- Switzerland
- /
- Life Sciences
- /
- SWX:BANB
Here's Why Bachem Holding AG's (VTX:BANB) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights
- Bachem Holding will host its Annual General Meeting on 24th of April
- Salary of CHF308.0k is part of CEO Thomas Meier's total remuneration
- The overall pay is 74% below the industry average
- Bachem Holding's three-year loss to shareholders was 10% while its EPS grew by 10% over the past three years
Shareholders may be wondering what CEO Thomas Meier plans to do to improve the less than great performance at Bachem Holding AG (VTX:BANB) recently. They will get a chance to exercise their voting power to influence the future direction of the company in the next AGM on 24th of April. Setting appropriate executive remuneration to align with the interests of shareholders may also be a way to influence the company performance in the long run. We think CEO compensation looks appropriate given the data we have put together.
Check out our latest analysis for Bachem Holding
How Does Total Compensation For Thomas Meier Compare With Other Companies In The Industry?
Our data indicates that Bachem Holding AG has a market capitalization of CHF6.0b, and total annual CEO compensation was reported as CHF752k for the year to December 2023. We note that's an increase of 25% above last year. While we always look at total compensation first, our analysis shows that the salary component is less, at CHF308k.
On comparing similar companies from the Swiss Life Sciences industry with market caps ranging from CHF3.6b to CHF11b, we found that the median CEO total compensation was CHF2.8m. In other words, Bachem Holding pays its CEO lower than the industry median. Moreover, Thomas Meier also holds CHF1.3m worth of Bachem Holding stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
Component | 2023 | 2022 | Proportion (2023) |
Salary | CHF308k | CHF298k | 41% |
Other | CHF444k | CHF306k | 59% |
Total Compensation | CHF752k | CHF604k | 100% |
Speaking on an industry level, nearly 35% of total compensation represents salary, while the remainder of 65% is other remuneration. It's interesting to note that Bachem Holding pays out a greater portion of remuneration through salary, compared to the industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
A Look at Bachem Holding AG's Growth Numbers
Over the past three years, Bachem Holding AG has seen its earnings per share (EPS) grow by 10% per year. In the last year, its revenue is up 8.6%.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's also good to see modest revenue growth, suggesting the underlying business is healthy. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.
Has Bachem Holding AG Been A Good Investment?
With a three year total loss of 10% for the shareholders, Bachem Holding AG would certainly have some dissatisfied shareholders. So shareholders would probably want the company to be less generous with CEO compensation.
In Summary...
The uninspiring share price returns contrasts with the strong EPS growth, suggesting that there may be other factors at play causing it to diverge from fundamentals. The upcoming AGM will provide shareholders the opportunity to raise their concerns and evaluate if the board’s judgement and decision-making is aligned with their expectations.
CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. That's why we did some digging and identified 1 warning sign for Bachem Holding that you should be aware of before investing.
Important note: Bachem Holding is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
Valuation is complex, but we're here to simplify it.
Discover if Bachem Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:BANB
Bachem Holding
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Flawless balance sheet with solid track record.